Publications by authors named "N Shinoura"
Article Synopsis
- - The study aims to explore sensory processing alterations in individuals with acquired brain injury (ABI), focusing on hypersensitivity and hyposensitivity across multiple sensory modalities (visual, auditory, tactile, olfactory, and gustatory).
- - Involving 68 patients with brain or spinal cord tumors, the research assessed cognitive and emotional functions while evaluating sensory sensitivity changes at two stages: after disease onset and post-surgery.
- - Findings revealed that a notable number of participants reported sensory abnormalities, especially in visual (hypersensitivity) and auditory/tactile (hyposensitivity), and some sensory changes were linked to depressive states, albeit the conclusions were not definitive.
Mismatch repair (MMR) gene deficiency is rarely observed in gliomas, a constitutional defect is associated with tumorigenesis in Lynch syndrome, and an acquired defect is associated with hypermutation after temozolomide treatment. However, the meaning of MMR gene deficiency in gliomas is unclear. Two cases of MMR-deficient glioblastomas are reported, and mutational status of oncogenes was compared between primary and recurrent tumor samples in a glioblastoma patient with Lynch syndrome.
View Article and Find Full Text PDFAwake craniotomy is an established procedure for resecting brain tumors in eloquent lesions, and intraoperative seizure is one of the most important complications. Phenytoin is normally used to control intraoperative seizures. Recently, phenytoin was replaced with levetiracetam at our institution because the latter has fewer side effects.
View Article and Find Full Text PDFA 46-year-old female patient with glioblastoma multiforme (GBM), IDH wild type developed severe pancytopenia 5 months after postoperative chemoradiotherapy. Bone marrow aspirate showed normocellular marrow with 70.0% abnormal cells, which suggested the possibility of acute myeloid leukemia.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to investigate genetic changes and determine good responders to treatment in newly diagnosed glioblastoma (GBM) patients enrolled in the JCOG0911 trial, comparing the effects of interferonβ (IFNβ) combined with temozolomide (TMZ) versus TMZ alone.
- Researchers analyzed 122 tumor samples using various sequencing methods to assess somatic mutations, promoter methylation, and tumor mutation burden, while also considering clinical factors like age and tumor location.
- Key findings revealed important genetic markers, including IDH1 mutations in 14% of tumors and MGMT promoter methylation in 41%, with total tumor resection and MGMT methylation identified as favorable prognostic factors, while tumors